Bionik Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has entered into a series of agreements to issue convertible notes of the Company for a total of up to US$2.0 million from current investors in the Company based in Europe. To date, Bionik has received funds of approximately US$800,000 in connection with the Loan.

"We are pleased to have completed this financing, which displays the ongoing belief of our investors in both our product platform as well as our ability to execute our strategic plan," said Dr. Eric Dusseux, Chief Executive Officer of Bionik Laboratories. "Our continued ability to access capital from existing and new investors and strategic partners has allowed us to further develop our commercial product line and seek entry into the residential medical device market."

The Company has used and intends to use the proceeds from the Loan for working capital purposes and to continue its efforts to commercialize and further develop its product platform, including the launch of its latest InMotion robotic interactive therapy systems later this year.

About Bionik Laboratories

Bionik Laboratories (OTCQB:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.

For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn, and Facebook.